Butyrate Inhibits Osteoclast Activity In Vitro and Regulates Systemic Inflammation and Bone Healing in a Murine Osteotomy Model Compared to Antibiotic-Treated Mice

Figure 1

Butyrate inhibits human osteoclast formation and resorption. Impact of butyrate on cells involved in bone healing. (a) Osteoclast precursor cells were cultured with 20 ng/mL M-CSF and 10 ng/mL RANKL and with 0.1 mM, 0.25 mM, 0.5 mM, or 1 mM butyrate, respectively. Osteoclast formation was quantified by means of TRAcP staining. Data shown are . Representative images showing TRAcP-stained osteoclasts in the absence (left image) and presence of 0.5 mM butyrate (right image). (b) Mature osteoclasts were cultured on a hydroxyapatite-coated plate in the presence and absence of butyrate with concentrations as indicated above. Resorption areas were quantified by means of von Kossa staining. Data shown are ( donor, performed in triplicate, and two pictures per well were taken and quantified). Representative images showing resorbed areas of hydroxyapatite-coated wells in the absence (left image) and presence of 0.5 mM butyrate (right image). (c) MSCs were cultured in osteogenic media and calcium deposits were quantified by means of Alizarin red staining in the absence and presence of 0.5 mM butyrate. Data shown are . Representative images of Alizarin red staining in the absence (left image) and presence of 0.5 mM butyrate (right image). Scale bar in all ; UT = untreated; RKL = RANKL; ; .

(a)

(b)

(c)